Deciphera Receives European Commission Approval Of Romvimza (Vimseltinib)

Refinitiv閱讀少於1分鐘

Ono Pharmaceutical Co Ltd 4528:

DECIPHERA RECEIVES EUROPEAN COMMISSION APPROVAL OF ROMVIMZA™ (VIMSELTINIB) FOR THE TREATMENT OF TENOSYNOVIAL GIANT CELL TUMOR (TGCT)

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

登入或建立一個永久免費帳戶來閱讀此新聞